Brown Advisory’s Humacyte HUMA Stock Holding History

Brown Advisory’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2K	Hold	13,129	–	–	﹤0.01%	1444
2026 Q1	$7.96K	Hold	13,129	–	–	﹤0.01%	1391
2025 Q4	$12.6K	Hold	13,129	–	–	﹤0.01%	1379
2025 Q3	$22.8K	Hold	13,129	–	–	﹤0.01%	1375
2025 Q2	$27.4K	Hold	13,129	–	–	﹤0.01%	1348
2025 Q1	$22.4K	Hold	13,129	–	–	﹤0.01%	1318
2024 Q4	$66.3K	Hold	13,129	–	–	﹤0.01%	1322
2024 Q3	$71.4K	Hold	13,129	–	–	﹤0.01%	1244
2024 Q2	$63K	Hold	13,129	–	–	﹤0.01%	1209
2024 Q1	$40.8K	Hold	13,129	–	–	﹤0.01%	1231
2023 Q4	$37.3K	Hold	13,129	–	–	﹤0.01%	1206
2023 Q3	$38.5K	Hold	13,129	–	–	﹤0.01%	1175
2023 Q2	$37.5K	Hold	13,129	–	–	﹤0.01%	1168
2023 Q1	$40.6K	Hold	13,129	–	–	﹤0.01%	1192
2022 Q4	$27.7K	Hold	13,129	–	–	﹤0.01%	1191
2022 Q3	$43K	Hold	13,129	–	–	﹤0.01%	1114
2022 Q2	$42K	Hold	13,129	–	–	﹤0.01%	1086
2022 Q1	$93K	Hold	13,129	–	–	﹤0.01%	1090
2021 Q4	$95K	Hold	13,129	–	–	﹤0.01%	1213
2021 Q3	$152K	Buy	+13,129	New	+$150K	﹤0.01%	1070

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory's HUMA Position: Q2 2026 in Review

Brown Advisory held its Humacyte (HUMA) position steady in Q2 2026 at 13,129 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Brown Advisory first reported a position in HUMA in Q3 2021 and has held it in 20 quarters since. The position peaked at $152K in Q3 2021. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Brown Advisory held 13,129 shares of Humacyte worth $10.2K as of Q2 2026.
Brown Advisory left its Humacyte share count unchanged in Q2 2026.
Humacyte made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #1444 holding.
Brown Advisory first reported a position in Humacyte in Q3 2021 and has held it in 20 quarters since.
Brown Advisory's Humacyte position peaked at $152K in Q3 2021.
163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.